The effect of soluble LAG-3 (CD223) treatment in fetal thymic organ culture

Taehoon Chun, Hyun Jung Byun, Yong Chung Hee, Yong Hoon Chung

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Lymphocyte activation gene-3 (LAG-3; CD223) is structurally similar to CD4 and binds to MHC class II with a 100-fold higher affinity than that of CD4. Soluble LAG-3 (sLAG-3Ig) might be useful for immunotherapy by inducing MHC class II-mediated cell activation. A new form of sLAG-3Ig was constructed containing a critical binding site (D1 and D2 region) to MHC class II, combined with a Fc portion of an immunoglobulin γ1. After treatment of sLAG-3Ig in fetal thymic organ culture from DO11.10 transgenic mouse, CD4 + T cell precursors were increased in the positive selection but not affected in the negative selection. Further analysis by treating sLAG-3Ig on thymic epithelial cells revealed that CD40 and MHC class II were up-regulated. These results may demonstrate that the treatment of sLAG-3Ig increases the precursor frequency of CD4 + T cells by activation of thymic epithelial cells.

Original languageEnglish
Pages (from-to)1371-1377
Number of pages7
JournalBiotechnology Letters
Volume26
Issue number17
DOIs
Publication statusPublished - 2004 Sep 1
Externally publishedYes

Fingerprint

Organ Culture Techniques
Cell culture
T-cells
Epithelial Cells
Chemical activation
T-Lymphoid Precursor Cells
Immunoglobulin Fc Fragments
Lymphocyte Activation
Immunotherapy
Transgenic Mice
Lymphocytes
Binding Sites
Binding sites
T-Lymphocytes
Therapeutics
Genes

Keywords

  • Co-receptor
  • Fetal thymic organ culture
  • Fusion protein
  • Lymphocyte activation gene-3
  • T cell precursor
  • Thymic selection

ASJC Scopus subject areas

  • Biotechnology
  • Applied Microbiology and Biotechnology
  • Microbiology
  • Bioengineering

Cite this

The effect of soluble LAG-3 (CD223) treatment in fetal thymic organ culture. / Chun, Taehoon; Byun, Hyun Jung; Hee, Yong Chung; Chung, Yong Hoon.

In: Biotechnology Letters, Vol. 26, No. 17, 01.09.2004, p. 1371-1377.

Research output: Contribution to journalArticle

Chun, Taehoon ; Byun, Hyun Jung ; Hee, Yong Chung ; Chung, Yong Hoon. / The effect of soluble LAG-3 (CD223) treatment in fetal thymic organ culture. In: Biotechnology Letters. 2004 ; Vol. 26, No. 17. pp. 1371-1377.
@article{9b9d7d35253647d6822a4bd533b94612,
title = "The effect of soluble LAG-3 (CD223) treatment in fetal thymic organ culture",
abstract = "Lymphocyte activation gene-3 (LAG-3; CD223) is structurally similar to CD4 and binds to MHC class II with a 100-fold higher affinity than that of CD4. Soluble LAG-3 (sLAG-3Ig) might be useful for immunotherapy by inducing MHC class II-mediated cell activation. A new form of sLAG-3Ig was constructed containing a critical binding site (D1 and D2 region) to MHC class II, combined with a Fc portion of an immunoglobulin γ1. After treatment of sLAG-3Ig in fetal thymic organ culture from DO11.10 transgenic mouse, CD4 + T cell precursors were increased in the positive selection but not affected in the negative selection. Further analysis by treating sLAG-3Ig on thymic epithelial cells revealed that CD40 and MHC class II were up-regulated. These results may demonstrate that the treatment of sLAG-3Ig increases the precursor frequency of CD4 + T cells by activation of thymic epithelial cells.",
keywords = "Co-receptor, Fetal thymic organ culture, Fusion protein, Lymphocyte activation gene-3, T cell precursor, Thymic selection",
author = "Taehoon Chun and Byun, {Hyun Jung} and Hee, {Yong Chung} and Chung, {Yong Hoon}",
year = "2004",
month = "9",
day = "1",
doi = "10.1023/B:BILE.0000045635.63873.96",
language = "English",
volume = "26",
pages = "1371--1377",
journal = "Biotechnology Letters",
issn = "0141-5492",
publisher = "Springer Netherlands",
number = "17",

}

TY - JOUR

T1 - The effect of soluble LAG-3 (CD223) treatment in fetal thymic organ culture

AU - Chun, Taehoon

AU - Byun, Hyun Jung

AU - Hee, Yong Chung

AU - Chung, Yong Hoon

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Lymphocyte activation gene-3 (LAG-3; CD223) is structurally similar to CD4 and binds to MHC class II with a 100-fold higher affinity than that of CD4. Soluble LAG-3 (sLAG-3Ig) might be useful for immunotherapy by inducing MHC class II-mediated cell activation. A new form of sLAG-3Ig was constructed containing a critical binding site (D1 and D2 region) to MHC class II, combined with a Fc portion of an immunoglobulin γ1. After treatment of sLAG-3Ig in fetal thymic organ culture from DO11.10 transgenic mouse, CD4 + T cell precursors were increased in the positive selection but not affected in the negative selection. Further analysis by treating sLAG-3Ig on thymic epithelial cells revealed that CD40 and MHC class II were up-regulated. These results may demonstrate that the treatment of sLAG-3Ig increases the precursor frequency of CD4 + T cells by activation of thymic epithelial cells.

AB - Lymphocyte activation gene-3 (LAG-3; CD223) is structurally similar to CD4 and binds to MHC class II with a 100-fold higher affinity than that of CD4. Soluble LAG-3 (sLAG-3Ig) might be useful for immunotherapy by inducing MHC class II-mediated cell activation. A new form of sLAG-3Ig was constructed containing a critical binding site (D1 and D2 region) to MHC class II, combined with a Fc portion of an immunoglobulin γ1. After treatment of sLAG-3Ig in fetal thymic organ culture from DO11.10 transgenic mouse, CD4 + T cell precursors were increased in the positive selection but not affected in the negative selection. Further analysis by treating sLAG-3Ig on thymic epithelial cells revealed that CD40 and MHC class II were up-regulated. These results may demonstrate that the treatment of sLAG-3Ig increases the precursor frequency of CD4 + T cells by activation of thymic epithelial cells.

KW - Co-receptor

KW - Fetal thymic organ culture

KW - Fusion protein

KW - Lymphocyte activation gene-3

KW - T cell precursor

KW - Thymic selection

UR - http://www.scopus.com/inward/record.url?scp=21644457592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21644457592&partnerID=8YFLogxK

U2 - 10.1023/B:BILE.0000045635.63873.96

DO - 10.1023/B:BILE.0000045635.63873.96

M3 - Article

C2 - 15604766

AN - SCOPUS:21644457592

VL - 26

SP - 1371

EP - 1377

JO - Biotechnology Letters

JF - Biotechnology Letters

SN - 0141-5492

IS - 17

ER -